Effect of intra-lipid in methadone toxicity

Evaluation of the effect of intravenous fat emulsion 20% infusion in controlling adverse effects of methadone toxicity in admitted patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201220049774N2

Enrollment

Registered

2022-01-19

Start date

2022-01-30

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poisoning by narcotics and psychodysleptics [hallucinogens]: Methadone. Poisoning by, adverse effect of and underdosing of methadone

Interventions

Intervention 1: Intervention group: In the intervention group, in addition to the standard treatment (naloxone), patients will receive a 20% intravenous fat emulsion at a dose of 1.5 ml / kg as an int

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Giving informed consent

Exclusion criteria

Exclusion criteria: History of pancreatitis with hyperlipidemia Known allergies eggs or soy proteins History of severe hyperlipidemia (serum triglyceride concentration greater than 1000 mg / dl) Acute shock History of severe hepatic impairment (child pugh class C) Acute heart attack Non-opioid poisoning Cerebrovascular events Taking other drugs that increase the QT interval

Design outcomes

Primary

Measure	Time frame
Number of breaths per minute. Timepoint: From before intervention to 5 hours after it per one hour. Method of measurement: Cardiac monitoring device.	—

Secondary

Measure	Time frame
QT intervale. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Systolic, diastolic and mean arterial blood pressure. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Shortness of breath, cyanosis and pupil size. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Physical examination.;Blood oxygen concentration level. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Level of consciousness. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Glosgow coma scale.;Heart rate. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Number of times naloxone is prescribed. Timepoint: 5 hours after intervention. Method of measurement: Patient nursing care cardex.	—

Measure

Time frame

QT intervale. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Systolic, diastolic and mean arterial blood pressure. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Shortness of breath, cyanosis and pupil size. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Physical examination.;Blood oxygen concentration level. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Level of consciousness. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Glosgow coma scale.;Heart rate. Timepoint: From before intervention to 5 hours after it hourly. Method of measurement: Cardiac monitoring device.;Number of times naloxone is prescribed. Timepoint: 5 hours after intervention. Method of measurement: Patient nursing care cardex.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHesamoddin Hosseinjani

Mashhad University of Medical Sciences

hosseinjanih@mums.ac.ir+98 51 3180 1586

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026